Menu
Recruiting NCT05730816

MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

Phase II Interventional Mesothelioma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Magnesium sulfate, Normal Saline.
Who it may be relevant to
Registry conditions: Mesothelioma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI

Overview

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

Detailed description

In this phase 2, open-label randomized, placebo-controlled trial, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of HIOC-associated AKI in patients with malignant mesothelioma undergoing surgery with HIOCC. Investigators will randomly assign 130 patients to receive IV Mg versus an equal volume of normal saline (0.9% NS) placebo, of whom it is anticipated 80 will complete the study. Investigators will also collect blood and urine pre- and postoperatively for exploration of secondary outcomes.

Investigators will screen for eligibility at participant's preoperative visit with their thoracic surgeon. Intravenous magnesium will be administered as a continuous infusion, soon after induction and stabilization by anesthesia in the operating room. The magnesium drip will start at 1 g/hour and will be titrated to achieve target levels of 3-5 mg/dl. The total duration of the infusion will be 24 hours.

Interventions

  • Drug Magnesium sulfate
    Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
  • Drug Normal Saline
    Intravenous infusion of normal saline.

Primary outcome measures

  • AUC of SCr measured daily over 7 days in Mg- versus placebo-treated patients [Time frame: 7 days]
  • Composite Global Rank [Time frame: 7 days]
Secondary outcome measures (9)
  • Incident AKI [Time frame: 7 days]
  • Composite outcome of RRT/in-hospital death [Time frame: 7 days]
  • Maximum AKI stage [Time frame: 7 days]
  • Renal tubular injury [Time frame: 2 days]
  • AUC for platinum concentrations [Time frame: 2 days]
  • Vasoactive-inotropic score (VIS) [Time frame: 2 days]
  • Proportion of patients with serum Mg levels in the 3-5 mg/dl range in the treatment group [Time frame: 1 day]
  • New onset of atrial fibrillation [Time frame: 7 days]
  • Myocardial injury [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

1\. • Adult patients (≥18 years old) with malignant mesothelioma undergoing surgery with HIOC with Dr. Raphael Bueno or another BWH thoracic surgeon

Exclusion criteria

  • eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Screening labs refer to those obtained at the preoperative visit with the surgeon or within 90 days prior, whereas preoperative labs are obtained on the day of admission (typically one to three days priors to surgery).
  • Serum Mg >3 mg/dl on either screening labs or preoperative labs
  • Pregnant/breastfeeding
  • Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myositis)
  • Coronary artery disease, defined as any of the following in the prior year: a positive stress test; coronary angiogram indicating 1 or more vessels with >70% stenosis; percutaneous coronary intervention with stents; or coronary artery bypass graft surgery
  • Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months
  • High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker
  • Positive COVID test in the 10 days prior to surgery
  • Prisoner
  • Hypersensitivity to Mg sulfate
  • Concurrent participation in a study with an alternative experimental therapy that may interact with IV Mg
  • Any condition that, in the view of the PI, might place the patient at increased risk or compromise the integrity of the study
  • Conflict with other study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • Brigham and Women's Hospital — Boston

Identifiers

NCT: NCT05730816 · 2023p000276 · K23DK125672

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗